Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Down 69.5% in November

by · The Markets Daily

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Get Free Report) saw a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 1,590,000 shares, a decrease of 69.5% from the November 15th total of 5,220,000 shares. Currently, 0.9% of the company’s shares are short sold. Based on an average trading volume of 34,310,000 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a research report on Saturday, December 7th. They set a “sell” rating for the company.

Check Out Our Latest Stock Analysis on TNXP

Tonix Pharmaceuticals Stock Performance

Shares of TNXP stock opened at $0.20 on Thursday. The stock’s 50-day moving average is $0.16 and its two-hundred day moving average is $0.70. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. Tonix Pharmaceuticals has a 1 year low of $0.12 and a 1 year high of $22.14. The firm has a market cap of $37.79 million, a price-to-earnings ratio of 0.00 and a beta of 2.23.

Tonix Pharmaceuticals (NASDAQ:TNXP – Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.82 million for the quarter, compared to the consensus estimate of $2.63 million. Analysts predict that Tonix Pharmaceuticals will post -17.63 earnings per share for the current year.

About Tonix Pharmaceuticals

(Get Free Report)

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

Further Reading